ALS Society

of Manitoba


La Société

Manitobaine de la SLA


Albrioza Discontinued

Posted on March 24, 2024 by Matthew Honey

The Canadian ALS Research Network (CALS) expressed disappointment at the negative outcomes of the PHOENIX Phase 3 trial for AMX0035, marketed as ALBRIOZA in Canada. Despite previous positive Phase 2 results, the 48-week study showed no significant benefit in slowing ALS progression compared to placebo. CALS recommends discontinuing AMX0035 for ALS treatment based on these findings. While frustrating, they remain hopeful for future ALS treatments and appreciate Amylyx’s support and transparency.

To read the full press release, follow the link below.

Albrioza Discontinued